Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
74,000
+5,000 (7.25%)
Sep 9, 2026, 3:30 PM KST
Mezzion Pharma Revenue
Mezzion Pharma had revenue of 2.20B KRW in the quarter ending June 30, 2026, with 26.18% growth. This brings the company's revenue in the last twelve months to 8.43B, up 6.92% year-over-year. In the year 2025, Mezzion Pharma had annual revenue of 7.91B, down -8.15%.
Revenue (ttm)
8.43B
Revenue Growth
+6.92%
P/S Ratio
268.71
Revenue / Employee
468.25M
Employees
18
Market Cap
2.26T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.91B | -702.12M | -8.15% |
| Dec 31, 2024 | 8.61B | -23.11B | -72.85% |
| Dec 31, 2023 | 31.72B | 994.76M | 3.24% |
| Dec 31, 2022 | 30.73B | 4.07B | 15.28% |
| Dec 31, 2021 | 26.65B | -1.98B | -6.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKook Pharmaceutical | 979.60B |
| Huons Global | 846.78B |
| PharmaResearch | 603.58B |
| ST Pharm | 386.46B |
| Sam Chun Dang Pharm. | 259.90B |
| BINEX | 157.28B |
| Oscotec | 144.18B |
| CG Invites | 30.11B |
Mezzion Pharma News
- 7 weeks ago - Mezzion Pharma's Udenafil Shows Promise for Fontan-Related Liver Disease - GuruFocus